Endoscopic therapy for Barrett's oesophagus

Christopher H. Blevins, Prasad G Iyer

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Barrett's oesophagus (BO) is thought to progress through the development of dysplasia (low grade and high grade) to oesophageal adenocarcinoma, a lethal cancer with poor survival. The overall goal of endoscopic therapy of BO is to eliminate metaplastic and dysplastic epithelium, to prevent and/or reduce the risk of progression to OAC. Endoscopic therapy techniques can be divided into two broad complementary techniques: tissue acquiring (endoscopic mucosal resection and endoscopic submucosal dissection) and ablative. Endoscopic therapy has been established as safe and effective for the subjects with intra-mucosal cancer (IMC), high-grade dysplasia (HGD) and more recently in treating low-grade dysplasia (LGD). Challenges to endoscopic therapy are being recognized, such as incomplete response and recurrence. While eradication of intestinal metaplasia is the immediate goal of endoscopic therapy, surveillance must continue after complete elimination of intestinal metaplasia, to detect and treat recurrences.

Original languageEnglish (US)
Pages (from-to)167-177
Number of pages11
JournalBest Practice and Research: Clinical Gastroenterology
Volume29
Issue number1
DOIs
StatePublished - Feb 1 2015

Fingerprint

Barrett Esophagus
Metaplasia
Therapeutics
Recurrence
Neoplasms
Adenocarcinoma
Epithelium

Keywords

  • Barrett's Oesophagus
  • Cryotherapy
  • Endoscopic mucosal resection
  • Endoscopic submucosal dissection
  • Endotherapy
  • Oesophageal adenocarcinoma
  • Radiofrequency ablation

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Endoscopic therapy for Barrett's oesophagus. / Blevins, Christopher H.; Iyer, Prasad G.

In: Best Practice and Research: Clinical Gastroenterology, Vol. 29, No. 1, 01.02.2015, p. 167-177.

Research output: Contribution to journalArticle

@article{fed2839be89a4fe296dda514a3bb3106,
title = "Endoscopic therapy for Barrett's oesophagus",
abstract = "Barrett's oesophagus (BO) is thought to progress through the development of dysplasia (low grade and high grade) to oesophageal adenocarcinoma, a lethal cancer with poor survival. The overall goal of endoscopic therapy of BO is to eliminate metaplastic and dysplastic epithelium, to prevent and/or reduce the risk of progression to OAC. Endoscopic therapy techniques can be divided into two broad complementary techniques: tissue acquiring (endoscopic mucosal resection and endoscopic submucosal dissection) and ablative. Endoscopic therapy has been established as safe and effective for the subjects with intra-mucosal cancer (IMC), high-grade dysplasia (HGD) and more recently in treating low-grade dysplasia (LGD). Challenges to endoscopic therapy are being recognized, such as incomplete response and recurrence. While eradication of intestinal metaplasia is the immediate goal of endoscopic therapy, surveillance must continue after complete elimination of intestinal metaplasia, to detect and treat recurrences.",
keywords = "Barrett's Oesophagus, Cryotherapy, Endoscopic mucosal resection, Endoscopic submucosal dissection, Endotherapy, Oesophageal adenocarcinoma, Radiofrequency ablation",
author = "Blevins, {Christopher H.} and Iyer, {Prasad G}",
year = "2015",
month = "2",
day = "1",
doi = "10.1016/j.bpg.2014.11.007",
language = "English (US)",
volume = "29",
pages = "167--177",
journal = "Best Practice and Research: Clinical Gastroenterology",
issn = "1521-6918",
publisher = "Bailliere Tindall Ltd",
number = "1",

}

TY - JOUR

T1 - Endoscopic therapy for Barrett's oesophagus

AU - Blevins, Christopher H.

AU - Iyer, Prasad G

PY - 2015/2/1

Y1 - 2015/2/1

N2 - Barrett's oesophagus (BO) is thought to progress through the development of dysplasia (low grade and high grade) to oesophageal adenocarcinoma, a lethal cancer with poor survival. The overall goal of endoscopic therapy of BO is to eliminate metaplastic and dysplastic epithelium, to prevent and/or reduce the risk of progression to OAC. Endoscopic therapy techniques can be divided into two broad complementary techniques: tissue acquiring (endoscopic mucosal resection and endoscopic submucosal dissection) and ablative. Endoscopic therapy has been established as safe and effective for the subjects with intra-mucosal cancer (IMC), high-grade dysplasia (HGD) and more recently in treating low-grade dysplasia (LGD). Challenges to endoscopic therapy are being recognized, such as incomplete response and recurrence. While eradication of intestinal metaplasia is the immediate goal of endoscopic therapy, surveillance must continue after complete elimination of intestinal metaplasia, to detect and treat recurrences.

AB - Barrett's oesophagus (BO) is thought to progress through the development of dysplasia (low grade and high grade) to oesophageal adenocarcinoma, a lethal cancer with poor survival. The overall goal of endoscopic therapy of BO is to eliminate metaplastic and dysplastic epithelium, to prevent and/or reduce the risk of progression to OAC. Endoscopic therapy techniques can be divided into two broad complementary techniques: tissue acquiring (endoscopic mucosal resection and endoscopic submucosal dissection) and ablative. Endoscopic therapy has been established as safe and effective for the subjects with intra-mucosal cancer (IMC), high-grade dysplasia (HGD) and more recently in treating low-grade dysplasia (LGD). Challenges to endoscopic therapy are being recognized, such as incomplete response and recurrence. While eradication of intestinal metaplasia is the immediate goal of endoscopic therapy, surveillance must continue after complete elimination of intestinal metaplasia, to detect and treat recurrences.

KW - Barrett's Oesophagus

KW - Cryotherapy

KW - Endoscopic mucosal resection

KW - Endoscopic submucosal dissection

KW - Endotherapy

KW - Oesophageal adenocarcinoma

KW - Radiofrequency ablation

UR - http://www.scopus.com/inward/record.url?scp=84925146623&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925146623&partnerID=8YFLogxK

U2 - 10.1016/j.bpg.2014.11.007

DO - 10.1016/j.bpg.2014.11.007

M3 - Article

C2 - 25743464

AN - SCOPUS:84925146623

VL - 29

SP - 167

EP - 177

JO - Best Practice and Research: Clinical Gastroenterology

JF - Best Practice and Research: Clinical Gastroenterology

SN - 1521-6918

IS - 1

ER -